Evolus to report second-quarter results after markets close, host conference callPUBT·Jul 22 at 07:30 AMEOLS-3.05%
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jul 10 at 03:17 PMEOLS-3.05%
10:31 ETRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing Itprnewswire·May 22 at 09:33 AMEOLS-3.05%IART-16.55%
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in EuropeUnusual Whales·May 11 at 07:34 AMEOLS-3.05%
Evolus (EOLS) Breakeven Q4 EPS Tests Skeptics Of Its Profitability PathSimplywall·May 6 at 05:08 AMEOLS-3.05%SBIO-0.60%
Evolus shares are trading higher after the company reported better-than-expected Q1 sales results.benzinga_article·May 5 at 10:02 AMEOLS-3.05%BBH-0.69%
Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target ReaffirmedTip Ranks·May 5 at 05:35 AMEOLS-3.05%IBB-1.04%
